Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a significant drop in short interest in the month of July. As of July 15th, there was short interest totaling 26,452 shares, a drop of 98.2% from the June 30th total of 1,511,367 shares. Based on an average daily volume of 67,658 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.2% of the shares of the company are short sold.

Enlivex Therapeutics Stock Down 3.7%

Enlivex Therapeutics stock traded down $0.16 during trading hours on Friday, hitting $4.20. 106,559 shares of the company traded hands, compared to its average volume of 69,542. Enlivex Therapeutics has a 1-year low of $4.08 and a 1-year high of $31.50. The firm has a market cap of $70.69 million, a P/E ratio of -0.51 and a beta of 1.52. The firm’s 50-day simple moving average is $8.85 and its two-hundred day simple moving average is $12.74.

Institutional Investors Weigh In On Enlivex Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd boosted its stake in Enlivex Therapeutics by 44.8% during the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after purchasing an additional 19,132 shares in the last quarter. Bank of America Corp DE increased its position in shares of Enlivex Therapeutics by 53.2% during the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after purchasing an additional 45,303 shares during the period. Virtu Financial LLC bought a new stake in shares of Enlivex Therapeutics in the 4th quarter worth $33,000. Jane Street Group LLC raised its stake in shares of Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock worth $52,000 after buying an additional 52,553 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in shares of Enlivex Therapeutics in the third quarter valued at $57,000. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ENLV. HC Wainwright boosted their price objective on Enlivex Therapeutics from $195.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. Finally, Zacks Research upgraded Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $247.50.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.